Banque Cantonale Vaudoise Sells 17,597 Shares of Abbott Laboratories $ABT

Key Points

• Banque Cantonale Vaudoise cut its Abbott Laboratories stake by 18.3% in the first quarter, selling 17,597 shares and leaving it with 78,755 shares valued at about $8.1 million.
• Abbott posted solid quarterly results, beating earnings and revenue estimates with EPS of $1.15 and revenue of $11.16 billion, while also issuing FY2026 guidance of $5.38 to $5.58 per share.
• Investor sentiment remains mixed: Abbott announced a 2.8% dividend yield and received mostly Buy ratings from analysts, but the stock still faces a legal overhang tied to the $495 million baby formula verdict appeal.

Banque Cantonale Vaudoise lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 18.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 78,755 shares of the healthcare product maker's stock after selling 17,597 shares during the quarter. Banque Cantonale Vaudoise's holdings in Abbott Laboratories were worth $8,085,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABT. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC grew its position in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares in the last quarter. United Bank increased its stake in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC raised its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after purchasing an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott signed a global licensing agreement with ALZpath to incorporate its pTau217 antibody into a blood-based Alzheimer’s diagnostic, a potentially meaningful addition to Abbott’s diagnostics portfolio. Reuters article
• Positive Sentiment: Reports highlighted growing momentum in Abbott’s emerging markets and EPD business, supported by branded generics demand, biosimilar expansion, and new approvals, which points to continued international growth. Article
• Positive Sentiment: MiniMed’s launch of Abbott Instinct sensors across European markets expands Abbott’s diabetes technology reach and reinforces the company’s connected care ecosystem. Article
• Positive Sentiment: Abbott was also featured in bullish commentary as a durable dividend aristocrat with 54 straight years of dividend increases, which may be supporting investor sentiment around the stock. Article
• Neutral Sentiment: Abbott continued to draw investor and analyst attention, with articles noting strong interest and a “Moderate Buy” consensus, but these are more sentiment indicators than new fundamental developments. Zacks article
• Negative Sentiment: A Missouri appeals court decision allowing Abbott’s $495 million preterm baby formula verdict appeal to remain in place keeps a major legal overhang on the shares. Article

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Price Performance

ABT opened at $90.46 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock's 50 day simple moving average is $89.39 and its 200 day simple moving average is $105.69. The firm has a market cap of $157.56 billion, a price-to-earnings ratio of 25.34, a PEG ratio of 1.56 and a beta of 0.63. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $138.84.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business's revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories's payout ratio is currently 70.59%.

Analyst Ratings Changes

Several brokerages have recently commented on ABT. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Oppenheimer dropped their target price on Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. BTIG Research reiterated a "buy" rating and set a $131.00 price target on shares of Abbott Laboratories in a research report on Monday, April 27th. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research note on Monday, April 20th. Finally, Argus lowered their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.30.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.